



Supplementary Material

Article Title: Impact of Once- vs Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

Author(s): Hiroyoshi Takeuchi, MD, PhD; Gagan Fervaha, BSc; Hiroyuki Uchida, MD, PhD; Takefumi Suzuki, MD, PhD; Robert R. Bies, PhD; David Grönte, MD; and Gary Remington, MD, PhD, FRCPC

DOI Number: 10.4088/JCP.13m08695

List of Supplementary Material for the article

1. [eTable 1](#) Treatment-Emergent Adverse Events in Once-Daily and Twice-Daily Dosing Groups
2. [eTable 2](#) Newly Started Concomitant Psychotropic Medications in Once-Daily and Twice-Daily Dosing Groups

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2014 Physicians Postgraduate Press, Inc.

Supplementary eTable 1. Treatment-Emergent Adverse Events^a in Once-Daily and Twice-Daily Dosing Groups

	Once-Daily Group (N=133)		Twice-Daily Group (N=124)		Group Difference <i>P</i> ^b
	N	%	N	%	
Any treatment emergent adverse event	119	89.5	111	89.5	1.00
Insomnia	56	42.1	53	42.7	1.00
Hypersomnia/sleepiness	60	45.1	66	53.2	0.21
Urinary hesitancy/dry mouth/constipation	53	39.8	53	42.7	0.70
Decreased sex drive/arousal/ability to reach orgasm	47	35.3	38	30.6	0.43
Gynecomastia/galactorrhea	8	6.0	9	7.3	0.80
Menstrual irregularities	8	6.0	6	4.8	0.79
Incontinence/nocturia	14	10.5	11	8.9	0.68
Orthostatic faintness	36	27.1	31	25.0	0.78

^aAdverse event was defined as treatment emergent adverse event if its severity was higher than the baseline during phase 1.

^bNo significant differences between the 2 groups

Supplementary eTable 2. Newly Started Concomitant Psychotropic Medications in Once-Daily and Twice-Daily Dosing Groups

		Once-Daily Group (N=133)		Twice-Daily Group (N=124)		Group Difference
		N or Mean	% or SD	N or Mean	% or SD	P
Any psychotropic medications	Rate of users	39	29.3	43	34.7	0.42
	Time to initiation (days)	103	116	88	96	0.52
	Duration of use (days)	144	166	144	181	0.99
Antidepressants	Rate of users	16	12.0	12	9.7	0.69
	Time to initiation (days)	120	123	109	84	0.79
	Duration of use (days)	142	140	110	143	0.56
Antiepileptics	Rate of users	4	3.0	5	4.0	0.74
	Time to initiation (days)	51	42	174	150	0.14
	Duration of use (days)	113	96	161	160	0.61
Antipsychotics	Rate of users	9	6.8	9	7.3	1.00
	Time to initiation (days)	99	124	142	128	0.48
	Duration of use (days)	16	31	12	10	0.70
Anxiolytics	Rate of users	21	15.8	17	13.7	0.73
	Time to initiation (days)	102	127	68	89	0.36
	Duration of use (days)	73	111	133	153	0.17
Hypnotics/sedatives	Rate of users	10	7.5	13	10.5	0.51
	Time to initiation (days)	217	157	88	100	0.03 ^a
	Duration of use (days)	104	99	95	95	0.81
Lithium	Rate of users	1	0.8	2	1.6	0.61
	Time to initiation (days)	8	NA	167	105	0.43
	Duration of use (days)	187	NA	222	293	0.94

^aNo significant difference between the 2 groups after Bonferroni correction (ie, *P* value multiplied by 6)

Abbreviation: SD; Standard Deviation